Jiangsu Kanion Pharmaceutical Co Ltd
SSE:600557
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.95
23.81
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Additional Paid In Capital
Jiangsu Kanion Pharmaceutical Co Ltd
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Jiangsu Kanion Pharmaceutical Co Ltd
SSE:600557
|
Additional Paid In Capital
¥93m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-7%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Additional Paid In Capital
¥14.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Additional Paid In Capital
¥1.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Additional Paid In Capital
¥3.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
21%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Additional Paid In Capital
¥17.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
30%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Additional Paid In Capital
¥858.7m
|
CAGR 3-Years
294%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jiangsu Kanion Pharmaceutical Co Ltd
Glance View
Jiangsu Kanion Pharmaceutical Co., Ltd. engages in the manufacturing and sale of Chinese patent medicine preparations and health products. The company is headquartered in Lianyungang, Jiangsu and currently employs 5,045 full-time employees. The company went IPO on 2002-09-18. The firm provides capsules, oral liquid, granules, electuary, tablets, pills, patch and injections. The firm's products are applied in gynecology, orthopedics, cardiovascular and cerebrovascular, anti-infective, anti-tumor and others. The firm distributes its products mainly within domestic markets.
See Also
What is Jiangsu Kanion Pharmaceutical Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
93m
CNY
Based on the financial report for Jun 30, 2024, Jiangsu Kanion Pharmaceutical Co Ltd's Additional Paid In Capital amounts to 93m CNY.
What is Jiangsu Kanion Pharmaceutical Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
-7%
Over the last year, the Additional Paid In Capital growth was -24%. The average annual Additional Paid In Capital growth rates for Jiangsu Kanion Pharmaceutical Co Ltd have been -19% over the past three years , -13% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
